Expectations Ahead of AACR 2021
Insights - The American Association for Cancer Research (AACR) annual meeting will be hosted this coming weekend (April 9-14). Below is data to look for that will … Continue Reading
PremiumAuthor Archives: D Mero
9Meters Announces Financing Amid Biotech Rout
Insights - 9Meters (NMTR) announced a $30M raise this morning, selling 30M shares at $1/share. After this deal, fully diluted share count is approximately 297M. At a … Continue Reading
Premium
Is Delcath’s Phase 3 Data Enough For The FDA?
Research - Delcath (DCTH) released preliminary data for their Phase 3 in metastatic ocular melanoma (mOM). The preliminary analysis included 79 of 91 (87%) treated patients. Final results on … Continue Reading
Premium9Meter’s NM-002 Showing Early Signs of PS Reduction
Insights - 9Meters (NMTR) had their KOL call to give an update on the NM-002 program for short bowel syndrome (SBS). Yesterday, NMTR also announced that their interim Phase 3 … Continue Reading
Premium
Expectations for MGTA-145 in Mobilizing Myeloma Patients for Transplant
Insights - Magenta presented data for their mobilizing agent MGTA-145 at the European Society for Blood and Marrow Transplantation (EBMT 2021). The data was not new, but it gave … Continue Reading
Premium9Meters Has a Novel MoA for SBS That Could Be Worth Billions
Research - 9 Meters (NMTR) is developing a novel treatment for short bowel syndrome (“SBS”) by focusing on slowing food transit time through the gastrointestinal (“GI”) tract. … Continue Reading
Premium
Bio Downturn Presents Buying Opportunity in These Names
Research - Nine Meters Biopharma (NMTR) NMTR has reported top-line Phase 1b/2a data for Short Bowel Syndrome (“SBS”). The gastrointestinal (“GI”) tract is the tract from the mouth to the … Continue Reading
Premium